Does an optimal therapeutic sequence exist in advanced non-small cell lung cancer?

Area of Science:

• Oncology
• Medical Oncology
• Pharmacology

Background:

• Many advanced non-small cell lung cancer patients need second-line treatment after chemotherapy.
• A significant portion of these patients maintain good performance status.

Purpose of the Study:

• To review current second-line therapeutic options for advanced non-small cell lung cancer.
• To provide an update on available treatments.

Main Methods:

• Literature review of therapeutic options for second-line treatment.
• Analysis of approved chemotherapeutic drugs and biologic agents.

Main Results:

• Docetaxel and pemetrexed are approved chemotherapeutic options; pemetrexed has superior tolerability.
• Erlotinib (tyrosine kinase inhibitor) is approved for second- and third-line treatment, showing activity in specific patient subgroups (adenocarcinoma, females, Asian ethnicity, EGFR mutations).

Conclusions:

• Pemetrexed is a preferred second-line option due to better tolerability and quality of life.
• Erlotinib is a viable option, especially for patients with specific characteristics, and may be considered for earlier use.
• A treatment decision tree can incorporate pemetrexed, docetaxel, or erlotinib for second-line therapy.